HIV and AIDS Trial, Recruiting NCT07574619 Sponsor: RTI International Condition: HIV and AIDS
Back to Hiv Aids

HIV and AIDS Trial, Recruiting

NCT07574619
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For Aim 1 (Focus Group Discussion):

  • People aged 18 or older who work in roles related to PrEP outreach or delivery in certain study areas — this can include both clinic and non-clinic roles
  • People aged 18 or older who are members of one of three regional community advisory boards connected to a previous study called CATALYST
  • People who are able and willing to take part in a focus group discussion
  • People who can speak English or the main language used at the health facility
  • People who are able and willing to sign a consent form

For Aim 2 (PrEP Follow-Up Visit):

  • People aged 18 or older who are attending a follow-up appointment for PrEP (a medication used to reduce the risk of HIV)
  • People who are able and willing to complete all parts of the study
  • People who can speak English or the main language used at the health facility
  • People who are able and willing to sign a consent form

For Aim 3 (Questionnaire and Interview):

  • People aged 18 or older who have used a couples' decision-making tool called CUPID
  • People aged 18 or older who work as a provider delivering the CUPID program or offering PrEP options at a health facility where CUPID is in use
  • People aged 18 or older who are health officials at a ministry or district level
  • People who are willing to complete a questionnaire and take part in an individual or paired interview
  • People who can speak English or the main language used at the health facility
  • People who are able and willing to sign a consent form

Who may not be able to join:

  • People who have any condition that, in the opinion of the study's lead investigators, would prevent them from giving informed consent, make participation unsafe, complicate the study results, or interfere with the study's goals (confirm with trial site)
  • For Aim 2 specifically: people aged 15 to 17 years old

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
RTI International
Registry
ClinicalTrials.gov
Start date
13 May 2026
Est. completion
1 March 2028

Where this trial is recruiting

Uganda

Primary endpoints

PrEP persistence

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov